摘要
Objective： To investigate the effects of brachytherapy with computed tomography-guided percutaneous radioactive 1-125 seeds interstitial implantation （ISI） synchronized chemotherapy and Chinese medicine （CM） for the treatment of advanced stage of non-small cell lung cancer （NSCLC）. Methods： Ninety patients diagnosed with NSCLC by biopsy were randomly assigned to three groups： the synchronized therapy group （A）, the chemotherapy plus CM-treated group （B）, and the chemotherapy-treated group （C）; a 2-month course of treatment was administered to them all. The effectiveness of treatment was evaluated based on tumor size, tumor markers （carcinoembryonic, squamous cell carcinoma-associated antigen, and cytokeratin 19 fragment）, clinical symptoms, and quality of life （QOL） in patients. Results： The total effective rates of Groups A to C were 83.33%, 46.67%, and 43.33%, respectively. The tumor markers were reduced obviously in Group A, showing significant difference compared with those in the other two groups. Additionally, QOL was elevated and cancer-related symptoms were alleviated more significant in Group A than those in Group C （all P〈0.05）. Conclusion： The synchronized therapy of 1-125 implantation with chemotherapy and CM was a safe therapeutic method and can be regarded as a new mode for treatment of advanced-stage NSCLC.
Objective： To investigate the effects of brachytherapy with computed tomography-guided percutaneous radioactive 1-125 seeds interstitial implantation （ISI） synchronized chemotherapy and Chinese medicine （CM） for the treatment of advanced stage of non-small cell lung cancer （NSCLC）. Methods： Ninety patients diagnosed with NSCLC by biopsy were randomly assigned to three groups： the synchronized therapy group （A）, the chemotherapy plus CM-treated group （B）, and the chemotherapy-treated group （C）; a 2-month course of treatment was administered to them all. The effectiveness of treatment was evaluated based on tumor size, tumor markers （carcinoembryonic, squamous cell carcinoma-associated antigen, and cytokeratin 19 fragment）, clinical symptoms, and quality of life （QOL） in patients. Results： The total effective rates of Groups A to C were 83.33%, 46.67%, and 43.33%, respectively. The tumor markers were reduced obviously in Group A, showing significant difference compared with those in the other two groups. Additionally, QOL was elevated and cancer-related symptoms were alleviated more significant in Group A than those in Group C （all P〈0.05）. Conclusion： The synchronized therapy of 1-125 implantation with chemotherapy and CM was a safe therapeutic method and can be regarded as a new mode for treatment of advanced-stage NSCLC.
